Latest & greatest articles for benazepril

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on benazepril or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on benazepril and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for benazepril

1. Benazepril

Benazepril Top results for benazepril - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for benazepril The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

2. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. (PubMed)

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. The optimal combination drug therapy for hypertension is not established, although current U.S. guidelines recommend inclusion of a diuretic. We hypothesized that treatment with the combination of an angiotensin-converting-enzyme (ACE) inhibitor and a dihydropyridine calcium-channel blocker would be more effective in reducing the rate of cardiovascular events than treatment with an ACE inhibitor plus (...) a thiazide diuretic.In a randomized, double-blind trial, we assigned 11,506 patients with hypertension who were at high risk for cardiovascular events to receive treatment with either benazepril plus amlodipine or benazepril plus hydrochlorothiazide. The primary end point was the composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, hospitalization for angina, resuscitation after sudden cardiac arrest, and coronary revascularization.The baseline characteristics

Full Text available with Trip Pro

2008 NEJM Controlled trial quality: predicted high

3. Efficacy and safety of benazepril for advanced chronic renal insufficiency. (PubMed)

Efficacy and safety of benazepril for advanced chronic renal insufficiency. Angiotensin-converting-enzyme inhibitors provide renal protection in patients with mild-to-moderate renal insufficiency (serum creatinine level, 3.0 mg per deciliter or less). We assessed the efficacy and safety of benazepril in patients without diabetes who had advanced renal insufficiency.We enrolled 422 patients in a randomized, double-blind study. After an eight-week run-in period, 104 patients with serum creatinine (...) levels of 1.5 to 3.0 mg per deciliter (group 1) received 20 mg of benazepril per day, whereas 224 patients with serum creatinine levels of 3.1 to 5.0 mg per deciliter (group 2) were randomly assigned to receive 20 mg of benazepril per day (112 patients) or placebo (112 patients) and then followed for a mean of 3.4 years. All patients received conventional antihypertensive therapy. The primary outcome was the composite of a doubling of the serum creatinine level, end-stage renal disease, or death

Full Text available with Trip Pro

2006 NEJM Controlled trial quality: predicted high

4. Economic evaluation of benazepril in chronic renal insufficiency

Economic evaluation of benazepril in chronic renal insufficiency Economic evaluation of benazepril in chronic renal insufficiency Economic evaluation of benazepril in chronic renal insufficiency van Hout B A, Simeon G P, McDonnell J, Mann J F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology Benazepril in the treatment of patients with chronic renal insufficiency. Type of intervention Treatment; Secondary prevention. Economic study type Cost-effectiveness analysis. Study population Patients aged between 18 and 70 years who experienced chronic renal insufficiency. Setting Hospital. The economic study was carried out in the Netherlands, Switzerland, and Germany. Dates to which data relate The effectiveness data were collected

1997 NHS Economic Evaluation Database.

5. Clinical and economic effects of replacing enalapril with benazepril in hypertensive patients

Clinical and economic effects of replacing enalapril with benazepril in hypertensive patients Clinical and economic effects of replacing enalapril with benazepril in hypertensive patients Clinical and economic effects of replacing enalapril with benazepril in hypertensive patients Briscoe T A, Dearing C J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Introduction of a programme aimed at encouraging treatment of hypertension using less costly angiotensin-converting-enzyme (ACE) inhibitors, namely, benazepril instead of enalapril for selected patients. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Outpatients being treated for hypertension (using enalapril) who did

1996 NHS Economic Evaluation Database.

6. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. (PubMed)

Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Drugs that inhibit angiotensin-converting enzyme slow the progression of renal insufficiency in patients with diabetic neuropathy. Whether these drugs have a similar action in patients with other renal diseases is not known. We conducted a study to determine the effect of the angiotensin (...) -converting-enzyme inhibitor benazepril on the progression of renal insufficiency in patients with various underlying renal diseases.In a three-year trial involving 583 patients with renal insufficiency caused by various disorders, 300 patients received benazepril and 283 received placebo. The underlying diseases included glomerulopathies (in 192 patients), interstitial nephritis (in 105), nephrosclerosis (in 97), polycystic kidney disease (in 64), diabetic nephropathy (in 21), and miscellaneous

1996 NEJM Controlled trial quality: uncertain